Clinical Trials

    A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/? Refractory Multiple Myeloma (iMMagine-3)

    Investigator: Siddhartha Ganguly

    Study Coordinator: Danielle Sewall

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06413498

    Phone: 346.238.2674

    Protocol Number: PRO00038239

    Description


    The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded independent review committee (IRC).